BioCentury | Mar 15, 2021
Finance

Cell and gene therapy accelerator ElevateBio continues to refine ‘sweet spot’ with $525M series C

...and Fidelity Management & Research Company participated in the round alongside existing investors MPM Capital, F2...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

...not provided details on development timelines but said it has enough capital to reach the clinic. F2...
...AndersonAcademic collaborators: MITCorporate partners: N/ANumber of employees: 25Funds raised: over $100 millionInvestors: MPM Capital, Taiho Ventures, F2...
BioCentury | Feb 23, 2021
Product Development

Meniere disease pipeline: Data Byte

...H1 receptor HRH3 – Histamine H3 receptor NFE2L2 (NRF2) – Nuclear factor (erythroid-derived 2)-like 2 PGF2ɑ – Prostaglandin F2 ɑ...
...AB Sound Pharmaceuticals Inc. Histamine H1 receptor (HRH1) Histamine H3 receptor (HRH3) Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2) Prostaglandin F2...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...round led by the UBS Oncology Impact Fund, which is managed by MPM Capital, and F2...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

...filed for IPOs on NASDAQ. Backed by MPM Capital, the UBS Oncology Impact Fund and F2...
BioCentury | Nov 19, 2020
Product Development

Preclinical POC for Codiak’s IL-12 therapy highlight retention benefits of exosomes

...for advanced solid tumors. Data are expected in mid-2021. TARGETSIL-12 – Interleukin-12 Danielle Golovin exoIL-12 exoSTING Codiak BioSciences Inc. Interleukin-12 (IL-12) Prostaglandin F2...
BioCentury | Nov 7, 2020
Product Development

Nov. 6 Quick Takes: Global Blood slides after earnings; plus AZ’s hold on fitusiran, U.K.’s vaccine delivery

...million figure had assumed a “linear yield on scale-up” with “no hiccups at all.”TARGETSAT3 (SERPINC1) – Anti-thrombin...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

...nanoparticles inhibited granule secretion induced by low-dose thrombin...
BioCentury | Jun 22, 2020
Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

...double digits. Targets BASP1 - Brain abundant membrane attached signal protein 1 PTGFRN - Prostaglandin F2...
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...week after the company announced a $98 million series B round (see “Founding Investors MPM, F2...
Items per page:
1 - 10 of 1065